These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33796146)

  • 1. Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study.
    Menge T; Rehberg-Weber K; Taipale K; Nastos I; Jauß M
    Ther Adv Neurol Disord; 2021; 14():17562864211000461. PubMed ID: 33796146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
    Centonze D; Fantozzi R; Buttari F; Grimaldi LME; Totaro R; Corea F; Marrosu MG; Confalonieri P; Cottone S; Trojano M; Zipoli V
    Front Neurol; 2021; 12():637615. PubMed ID: 33967938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study.
    Al-Roughani R; Zakaria M; Cupler EJ; Taha K
    Front Neurol; 2023; 14():1257455. PubMed ID: 38090266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
    Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.
    Kolb-Mäurer A; Sunderkötter C; Kukowski B; Meuth SG;
    BMC Neurol; 2019 Jun; 19(1):130. PubMed ID: 31202258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
    Salvetti M; Wray S; Nelles G; Altincatal A; Kumar A; Koster T; Naylor ML;
    Mult Scler Relat Disord; 2022 Jan; 57():103350. PubMed ID: 35158459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
    Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
    Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
    Hendin B; Naismith RT; Wray SE; Huang D; Dong Q; Livingston T; Jones DL; Watson C; Jhaveri M
    Patient Prefer Adherence; 2018; 12():1289-1297. PubMed ID: 30050291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.
    Newsome SD; Scott TF; Arnold DL; Nelles G; Hung S; Cui Y; Shang S; Naylor ML; Kremenchutzky M
    Ther Adv Neurol Disord; 2018; 11():1756286418791143. PubMed ID: 30181778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Hoy SM
    CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program.
    Salvetti M; Wray S; Nelles G; Belviso N; Kumar A; Koster T; Castro-Borrero W; Vignos M;
    Mult Scler J Exp Transl Clin; 2024; 10(2):20552173241238632. PubMed ID: 38784791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
    Newsome SD; Kieseier BC; Liu S; You X; Kinter E; Hung S; Sperling B
    Ther Adv Neurol Disord; 2017 Jan; 10(1):41-50. PubMed ID: 28450894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers.
    Zhao Y; Chen K; Ramia N; Sahu S; Kumar A; Naylor ML; Zhu L; Naik H; Butts CL
    Ther Adv Neurol Disord; 2021; 14():1756286420975227. PubMed ID: 33628334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of peginterferon-β-1a in the therapy of multiplex sclerosis].
    Simó M; Iljicsov A
    Ideggyogy Sz; 2017 Nov; 70(11-12):365-368. PubMed ID: 29870644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.